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Acute bronchiolitis is defined as viral-induced inflammation of 
bronchioles. The clinical manifestations occur as a consequence 
of airway inflammation and air trapping. 
Bronchiolitis most commonly occurs as an acute illness in 
children younger than 2 years of age. The most frequent cause 
is rhinovirus or respiratory syncytial virus (RSV) infection, 
other respiratory viruses being less common (Table I). The 
illness is generally self-limiting. Patients often feed poorly 
and have mild upper respiratory tract infection (URTI) signs, 
low-grade fever, hyperinflation of the chest and wheezing. 
Symptoms of severe illness include tachypnoea and lower chest 
wall retractions.1 Bronchiolitis must be differentiated from 
aspiration of a foreign body, in which URTI signs are lacking.
The most reliable clinical feature of bronchiolitis is 
hyperinflation of the chest, evident by loss of cardiac dullness 
on percussion, an upper border of the liver pushed down to 
below the 6th intercostal space, and the presence of a ‘Hoover 
sign’ (subcostal recession, which occurs when a flattened 
diaphragm pulls laterally against the lower chest wall). Diffuse 
expiratory wheezing is common.  
1. Causative organisms 
The most common respiratory viruses associated with 
bronchiolitis are listed in Table I.
Many studies now show rhinovirus to be a cause of 
bronchiolitis, particularly mild bronchiolitis. Rhinovirus 
infection is identified in older children more frequently than 
RSV-associated bronchiolitis (median ages 13 v. 5 months, 
respectively) and is often associated with atopic disease (atopic 
dermatitis and blood eosinophilia).2 Oxygen saturation is 
generally not as low in children with rhinovirus-associated 
bronchiolitis as in children with RSV-associated bronchiolitis.2 
Rhinovirus appears to be a perennial isolate in South African 
children.  
RSV is the commonest cause of moderate or severe 
bronchiolitis. Two RSV subtypes occur, which are genotypically 
characterised by the nucleotide sequence of the virus 
glycoprotein (G-protein).3 The existence of distinct lineages 
within the subgroups has been demonstrated on both antigenic 
and nucleotide levels.4 South African subgroup A and B isolates 
cluster into four and ﬁve genotypes, respectively. Different 
genotypes co-circulate in every season. There is some evidence 
that group A RSV is associated with more severe disease.5 
2. Seasonality of RSV infection
There are several factors responsible for an outbreak of RSV 
infection. These include geographical locations (latitude 
and altitude) and climatic factors (temperature, barometric 
pressure, relative humidity, vapour tension, hours of light, 
precipitation, dewpoint).
In most temperate regions, such as the USA and Europe, 
RSV outbreaks last an average of 3 - 4 months with a peak 
incidence during winter, although the exact timing of the onset 
of the outbreak is uncertain. In tropical regions such as The 
Gambia and Singapore, RSV outbreaks do not have distinct 
seasonality but often occur during the hottest rainy season. In 
South Africa, the seasonality of RSV outbreaks varies between 
the different regions and from year to year. In Cape Town, in 
one year, a biennial peak was seen, the first in the rainy season 
and the second between autumn and winter. In Gauteng the 
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Objective. To develop and publish a guideline for doctors 
managing acute viral bronchiolitis, because this condition 
is extremely common in South Africa, it is responsible for 
significant morbidity in the population, and subsequently a 
great deal of patient and parental distress, and the disease 
is costly, since many children are unnecessarily subjected to 
investigations and treatment strategies that are of no proven 
benefit. The main aims of the guideline are to promote an 
improved standard of treatment based on understanding 
of the disease and its management, and to encourage cost-
effective and appropriate management. 
Evidence. A detailed literature review was conducted and 
summarised into this document by a selected working group 
of paediatricians from around the country.
Recommendations. These include the appropriate diagnostic 
and management strategies for acute viral bronchiolitis.
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Table I. Respiratory viruses causing bronchiolitis
Respiratory syncytial virus
Rhinovirus
Parainfluenza virus (especially type 3)
Influenza virus
Adenovirus
Human metapneumovirus
Bocavirus
Coronavirus
Measles virus
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epidemic begins in late February and ends in August, while 
along the KwaZulu-Natal coast the pattern follows that of the 
tropics with a peak between February and March, during the 
rainy season. RSV may be identified throughout the year in 
HIV-infected children because of prolonged shedding of the 
virus (up to 100 days postinfection), compared with shedding 
of 5 - 7 days in HIV-uninfected children.6
3. Clinical manifestations and 
diagnosis
Bronchiolitis may be diagnosed on the basis of clinical 
signs and symptoms. The clinical pattern of wheezing and 
hyperinflation in a young child is diagnostic. The illness may 
have a seasonal tendency coinciding with the peak in RSV 
circulation. Chest radiographs and blood testing are generally 
unhelpful. Measurement of peripheral arterial oxygen 
saturation is useful to indicate the need for supplemental 
oxygen. A saturation less than 92% at sea level and 90% inland 
indicates that the child requires hospital admission for oxygen. 
Routine measurement of C-reactive protein does not aid in 
management.7  
3.1 Features of severe disease  
Bronchiolitis is usually mild but may cause more severe 
morbidity, including the need for hospitalisation, especially in 
children who have underlying risk factors for severe disease 
(Table II). In the USA, rates of hospitalisation of infants with 
bronchiolitis increased substantially during 1980 - 1996.8 
However, it is an uncommon cause of mortality.9 
Human metapneumovirus (hMPV) may produce severe 
bronchiolitis requiring intensive care unit (ICU) admission.10 
Between 1994 and 1996, the average observed incidence of 
hospital admissions of children younger than 1 year living 
in Banjul, The Gambia, with acute lower respiratory tract 
infections (ALRTIs) was 5.27 per 100 child-years; the rate for 
RSV-associated severe respiratory illness was 0.87 per 100 
child-years, and that for RSV-associated hypoxaemia 0.11 per 
100 child-years.11 In The Gambia in 1994 - 1996, RSV accounted 
for 19% of ALRTI hospitalisations and had a mortality rate 
of 0 - 0.5%.11 In the ICU, RSV infection was associated with 
a mortality rate of 3 - 5%.11 Mortality from RSV LRTI in 
industrialising countries is higher than in industrialised 
countries. In part this may be because a disproportionately 
greater percentage of RSV LRTIs in industrialising countries 
are associated with pneumonia and concurrent bacterial 
co-infection rather than bronchiolitis.
Severe disease is present if a child is hypoxic, has severe 
respiratory distress (tachypnoea, nasal flaring or lower chest 
retractions), is unable to feed or play because of shortness of 
breath, or has apnoea. Bronchiolitis with bronchopneumonia or 
hypoxia may require admission or mechanical ventilation.
3.2 Bacterial co-infection – risk and antibiotic use
Uncomplicated bronchiolitis in immunocompetent children 
is usually a self-limiting illness, and secondary bacterial 
infection is uncommon. However, immunosuppressed 
children or those presenting with severe illness may have 
higher rates of bacterial co-infection.12-14 Risk factors for 
bacteraemia among children with RSV bronchiolitis include 
severe presentation, ICU admission, nosocomial acquisition 
of RSV or cyanotic congenital heart disease.12 Among children 
with RSV bronchiolitis admitted to an ICU, especially those 
who required mechanical ventilation, the risk of bacteraemia 
was almost 4-fold that in children who did not require ICU 
admission.12 Further support for the role of bacterial-viral co-
infection in children who develop severe respiratory disease 
is provided by comparing rates of hospitalisation for severe 
viral pneumonia in children immunised with pneumococcal 
conjugate vaccine with those in unimmunised children. Among 
immunised children, the number of hospitalisations for viral 
pneumonia was reduced by approximately 30% compared with 
unimmunised children.15 HIV-infected children have a higher 
risk of bacteraemia than HIV-uninfected children.16 Moreover, 
bacterial-viral co-infection is more common in HIV-infected 
children hospitalised with LRTI than in immunocompetent 
children.17 
There are very few randomised trials of the use of antibiotics 
in children with bronchiolitis.18,19 A Cochrane review found no 
evidence for the use of antibiotics in bronchiolitis, as antibiotics 
did not impact on the primary outcome (time to resolution 
of signs or symptoms) or on secondary outcomes (hospital 
admission, duration of hospitalisation, need for re-admission, 
complications or radiological findings).16 However, only 1 
study18 of reasonable quality was identified that could be 
included in this review. In this study, infants were randomised 
either to ampicillin or placebo. Outcomes in 2 additional 
studies of poorer methodological quality have also shown no 
evidence for use of antibiotics in bronchiolitis.16,19 
The available evidence suggests that antibiotics should not 
be used in uncomplicated bronchiolitis. For children with more 
severe disease, requiring ICU admission or with risk factors for 
severe disease, antibiotics should be considered.
4. Management 
Management should include: 
•   treating the symptoms 
•    treating the underlying cause of the disease (infection and 
inflammation) 
•   preventing complications.
The following supportive treatments have been used for 
management of bronchiolitis (Table III): 
•   humidified oxygen
•   bronchodilator therapy 
•   nebulised hypertonic (3%) saline
•    anti-inflammatory therapy (corticosteroids – oral and 
nebulised) 
•    in-hospital use of antiviral treatments, e.g. ribavirin in 
ventilated children
•   montelukast. 
Table II. Risk factors for severe bronchiolitis
Environmental factors. Poverty, passive smoke exposure, 
pollution, overcrowding, day care centre attendance 
Host factors. Prematurity, congenital heart disease (CHD), 
chronic lung disease (CLD) of prematurity, neurological disease, 
infants <6 months, immunodeficiency, lack of breastfeeding
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Humidified low-flow oxygen (0.5 - 3 litres/minute) applied 
by nasal prongs is effective for hypoxic children. Nasal prongs 
give a maximum inspired oxygen of 28 - 35% except in small 
infants, when higher oxygen concentrations may be obtained. 
Headbox oxygen is an alternative that is well tolerated by 
young infants. It requires no humidification, but high flow 
and a mixing device are needed to ensure that the correct 
oxygen concentration is delivered.  However, there is wastage 
of oxygen and the delivered oxygen concentration (FiO2) is 
unpredictable. Facemask oxygen delivers between 28% and 
65% oxygen at a flow rate of 6 - 10 l/min. In severely hypoxic 
infants who are not ventilated, oxygen should be administered 
using a polymask, which enables FiO2 concentrations of 60 - 
80% to be achieved. 
Oxygen should be weaned when the child improves 
clinically and with resolution of hypoxia. 
Rapid short-acting bronchodilator therapy has shown 
modest benefits in the treatment of bronchiolitis.20 
Bronchodilators may produce short-term improvements in 
clinical signs, but have not been shown to affect any important 
clinical outcome, such as obviating the need for ventilation 
or reducing inpatient stay.21 A Cochrane review (22 clinical 
trials with 1 428 infants) found that almost 60% of children 
treated with bronchodilators had a modest improvement in 
clinical score, but there was no impact on oxygenation, need 
for hospitalisation or duration of hospitalisation.21 For studies 
of adrenaline use, only 1 (of 5) demonstrated modest benefit 
compared with placebo and 1 (of 7) modest benefit compared 
with salbutamol.22 Furthermore, these improvements must be 
considered against the cost of the medications, and the need to 
handle and therefore distress the infant. Ipratropium bromide 
is ineffective in the treatment of bronchiolitis.23
In some children with severe disease a trial of a 
bronchodilator (adrenaline or β2-agonist by spacer with 
facemask (preferably) or by nebulisation) is acceptable. 
However, if there is a lack of response (improvement in 
oxygen saturation or reduction in signs of respiratory distress) 
following three consecutive doses of bronchodilator, this form 
of therapy should cease. In children who respond, ongoing use 
may be appropriate until there is resolution of signs of severity. 
The optimal frequency, dosage and duration of bronchodilator 
therapy in these children have not been established. 
Hypertonic saline given as nebulised 3% or 5% saline may 
significantly reduce the length of hospital stay and improve the 
clinical severity score in infants with acute viral bronchiolitis.24 
However, data on dose and frequency are inconsistent. Some 
studies use 2 ml, while most use 4 ml delivered with or 
without bronchodilator agents.24 Dosing frequency ranges from 
2- to 6-hourly.
Oral corticosteroids have little or no effect on the clinical 
outcome of bronchiolitis and are therefore not routinely 
recommended.25-27 A recent study reported that prednisolone 
(2 mg/kg per day in 3 divided doses for 3 days) may have 
some benefit in rhinovirus-induced bronchiolitis.28 Prednisone 
decreases the rate of relapses (22% v. 57%) (odds ratio (OR) 
19.06, confidence interval (CI) 2.52 - 144.03).28 However, 
rhinovirus bronchiolitis is usually mild. In contrast, prednisone 
did not appear to reduce the severity or duration of illness 
in children with RSV-associated bronchiolitis. Studies have 
also shown no evidence of benefit for injectable systemic 
steroids.29,30
Two randomised controlled trials showed no evidence 
of benefit for inhaled corticosteroids (ICS) in acute 
bronchiolitis.31,32  Routine use of systemic or inhaled steroids in 
the management of bronchiolitis is therefore not indicated. 
Furthermore, there is no evidence that use of ICS reduces 
wheezing after bronchiolitis.33,34 The use of ICS during or after 
bronchiolitis is therefore not indicated.
Montelukast has no effect on the clinical course of 
bronchiolitis or its outcome. A study of montelukast (4 mg 
Table III. Treatment strategies for bronchiolitis illustrating those that are effective and those that are minimally or not 
effective
                  Possible adverse events, 
Intervention                Benefit               disadvantages   Recommendation
Oxygen                 Hypoxic infants              Few    Use for hospitalised
          infants with room air
          oxygen saturation 
          <90/92%
Inhaled                 Modest               Tachycardia, hypokalaemia  Trial in hypoxic infants
bronchodilators                 Cost
via MDI-spacer
Nebulised adrenaline             Some               As above    Trial in  hypoxic infants
Nebulised 3% saline               Yes               Increasing respiratory distress  Trial in hypoxic infants
Systemic corticosteroids         None               Mood disturbance   No value
Nebulised corticosteroids       None               Local thrush, hoarseness  No value
Inhaled corticosteroids           None               Local thrush, hoarseness  No value
via MDI-spacer or DPI
Montelukast                None               Cost    No value
Ribavirin                 Doubtful               Cost    No value
Chest physiotherapy              None               Discomfort     No value
                  Increasing respiratory
                  distress and hypoxia
MDI = metered dose inhaler; DPI = dry powder inhaler.
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daily until discharge) found no improvement in the clinical 
course of the disease. Montelukast also had no significant effect 
on the T-helper 2/T-helper 1 cytokine ratio when given in the 
early acute phase.35 In a study of post-bronchiolitis wheeze, 
montelukast did not improve respiratory symptoms of post-
RSV bronchiolitis in children.36 
Similarly, ribavirin has not been shown to have any 
consistent effect in the management of bronchiolitis.37
The use of chest physiotherapy has not been shown to 
change the course of bronchiolitis or its outcome. Chest 
physiotherapy using vibration and percussion techniques does 
not reduce length of hospital stay or oxygen requirements 
or improve the severity clinical score in infants with acute 
bronchiolitis.38
4.1 Indications for hospitalisation
The majority of infants with bronchiolitis do not require 
hospitalisation, but certain children are at risk of severe disease 
or require oxygen39-41 (Table IV).
There is no evidence that clinical scoring systems perform 
better than clinical judgement in deciding who needs 
admission to hospital.42 Infants with bronchiolitis may 
deteriorate for 2 - 3 days after the onset of symptoms before 
symptoms and signs start to resolve. 
4.2. Indications for ICU admission
The following are indications for ICU admission: 
•    failure to maintain an oxygen saturation of >90% on 
an inspired oxygen concentration of ≥70% (i.e. on a 
polymask), or if the arterial partial pressure of oxygen 
to fractional inspired oxygen (PaO2/FiO2) ratio is <100 
(normal 350) if arterial blood gas measurements are 
available
•   apnoea 
•   hypercarbia with resulting acidaemia (pH <7.25)
•    exhaustion, which may be difficult to judge but should be 
considered if a high respiratory rate or severe chest wall 
indrawing persists.
4.3 Management of severe disease
Infants with bronchiolitis who require paediatric ICU 
admission may have co-infection with bacteria, and antibiotics 
should be considered. In addition, ventilation should be with 
minimum positive end-expiratory pressure (PEEP), low tidal 
volumes (6 - 8 ml/kg) and minimum positive inspiratory 
pressure (PIP). Since this is an airway disease, air-trapping is a 
feature of the condition and auto-PEEP occurs. 
4.4 Infection control in hospital
RSV is spread predominantly by droplet spread and direct 
inoculation. Hospital-acquired outbreaks of bronchiolitis occur 
and must be prevented. All reasonable barrier and isolation 
procedures must be adopted by hospital staff when caring for 
sick children. Careful hand-washing between patients is the 
most important infection control measure and the mainstay 
of prevention. Children hospitalised with RSV should be 
cohorted with other RSV-infected children or with patients 
who are not at risk for severe disease. 
5. Prevention of RSV in high-risk 
children
Specific RSV monoclonal antibody, palivizumab, is available 
for children at risk of severe bronchiolitis. In a randomised, 
double-blind, placebo-controlled trial including 1 287 children 
with congenital heart disease (CHD) randomly assigned 
to receive 5-monthly intramuscular injections of 15 mg/kg 
palivizumab or placebo, palivizumab recipients had a 45% 
relative reduction in RSV hospitalisations (p=0.003), a 56% 
reduction in total days of RSV hospitalisation per 100 children 
(p=0.003) and a 73% reduction in total RSV hospital days 
requiring supplemental oxygen per 100 children (p=0.014).43 In 
the IMpact-RSV Study, significantly lower RSV hospitalisation 
rates were observed among premature infants who received 
palivizumab than among those who received placebo in each 
of the subgroups. The highest reduction in hospitalisation rate 
was seen in infants of gestational age 32 - 35 weeks, where 
RSV prophylaxis with palivizumab reduced hospitalisations 
by 80% (p=0.002).44 The efficacy of palivizumab was a 47% 
reduction in hospitalisations in infants with a gestational age 
<32 weeks.44 Palivizumab is therefore indicated in premature 
infants or young children with an underlying risk factor for 
severe disease (Table V). It should be remembered that in South 
Africa, because of resource constraints, these recommendations 
may need to be subject to cost-efficacy studies.
Table V. Indications for palivizumab
1.    Premature infants of gestational age <32 weeks at birth. 
Prophylaxis should be continued until the earlier of:
•   6 months of chronological age, or
•   the end of the RSV season (last dose in July) 
2.    Premature infants of gestational age 32 - 36 weeks at birth. 
Prophylaxis should be continued until the earlier of:
•   3 months of chronological age, or
•   the end of the RSV season (last dose in July) 
3.    Children of any gestation who are <24 months of age at the 
start of the RSV season with any of the following: chronic 
lung disease of prematurity, chronic lung disease, primary 
immunodeficiency, cyanotic congenital heart disease. 
Prophylaxis should be used for 5 months beginning in 
February in most areas of South Africa except for KwaZulu-
Natal, where it should be started in December 
4.    High-risk premature infants should commence their 
prophylaxis while still in hospital
Table IV. Indications for hospitalisation of an infant with 
bronchiolitis
Oxygen saturation <90% (inland) or 92% (coast)
Severe respiratory distress (cyanosis, grunting, or lower chest 
wall recession)
Poor feeding
Apnoea
Premature infants with associated risk factors
Underlying medical condition (congenital heart disease, chronic 
lung disease, Down syndrome) or risk factor for severe disease
Severe malnutrition
Family unable to provide appropriate care
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The recommended dose of palivizumab is 15 mg/kg body 
weight per dose, administered intramuscularly monthly. 
There are two dosing vials available – 15 mg and 30 mg. Since 
the seasonality of RSV in South Africa varies by province, 
it is recommended that prophylaxis be given for 5 months, 
beginning in December in KwaZulu-Natal and in February for 
the rest of the country. 
5.1 Recurrent viral-induced wheeze
RSV-associated bronchiolitis is associated with an increased 
risk of recurrent wheezing episodes in as many as 43% of 
children.45 To date, there are no effective treatment strategies 
that reduce this risk. The reader is referred to the latest South 
African Childhood Asthma Working Group (SACAWG) asthma 
guideline for management of recurrent wheeze.46 
6. Patient education 
Education of parents and caregivers is a vital part of the 
successful management of bronchiolitis. Anxiety will 
compromise attempts to limit unnecessary medication use. 
The following principles regarding bronchiolitis should be 
explained to parents or caregivers:
•   Generally the condition is not serious.
•   Most cases do not require medication.
•   Antibiotics are of no value.
•   Parents must monitor respiratory symptoms and report 
concerns to their doctor.
•    Symptoms may continue for weeks following the acute 
illness.
A useful patient education brochure may be found at: 
http://en.wikipedia.org/wiki/Bronchiolitis
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